New radiation drug targets bone tumors with less marrow harm
NCT ID NCT06982222
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 33 times
Summary
This early-stage trial tests a new version of a radiation drug (Sn-117m-DTPA) designed to target tumors that have spread to the bones from prostate, breast, or lung cancer. The drug delivers low-level radiation directly to bone tumors while being gentler on the bone marrow. The study will enroll 24 adults to find the safest dose and check for side effects. It does not aim to cure the cancer, but to control the disease and possibly slow tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.